SHORT REPORT

A skewed thiopurine metabolism is a common clinical phenomenon that can be successfully managed with a combination of low-dose azathioprine and allopurinol

Malin Lindqvist Appell a, Agnieszka Wagner b, Ulf Hindorf c,∗

a Division of Drug Research/Clinical Pharmacology, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden
b Department of Medicine, Blekinge Hospital, Karlskrona, Sweden
c Department of Gastroenterology, Skåne University Hospital, Lund, Sweden

Received 8 October 2012; received in revised form 21 October 2012; accepted 26 October 2012

KEYWORDS
Thiopurine methyltransferase; Thiopurines; Inflammatory bowel diseases

Abstract

Background and aims: A skewed thiopurine metabolism is a phenomenon associated with both poor treatment response and toxicity. Our aim was to evaluate the frequency of this phenomenon and the relationship to thiopurine methyltransferase (TPMT) function.

Methods: All thiopurine metabolite measurements in adult patients (n = 4033) between January 2006 and April 2012 were assessed to evaluate the occurrence of a skewed metabolism and the relationship to TPMT genotype and activity.

Results: A skewed metabolism was observed in 14% of all patients. It only developed in patients with a normal TPMT genotype, but was observed at all TPMT activity levels within the normal range (9.1–24.2 U/ml RBC). Two cases that illustrate typical clinical scenarios of a skewed metabolism and the effect of combination treatment with low-dose azathioprine and allopurinol are presented.

Conclusions: A skewed metabolism is a common clinical phenomenon in patients with a normal TPMT function, which can develop at all TPMT activity levels within the normal range. We suggest that metabolite measurements should be considered in patients not responding to treatment and in those with hepatotoxicity or myelotoxicity in order to detect a skewed metabolism, since this phenomenon can be successfully managed by a combination of low-dose azathioprine and allopurinol.

© 2012 European Crohn’s and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
1. Introduction

Treatment failure is a common clinical problem during thiopurine treatment of inflammatory bowel disease (IBD) and it has been shown that about 50% of all patients are either intolerant or refractory to standard thiopurine therapy. A skewed or aberrant thiopurine metabolism was recognized as a phenomenon associated with poor treatment response and hepatotoxicity. The high levels of methylated metabolites seen in a skewed metabolism have also been associated with an increased risk of developing myelotoxicity during therapy.

A way to overcome this aberrant metabolism is to reduce the thiopurine dose to about 25–33% of the original dose and add allopurinol. This treatment regimen has been shown to reverse the skewed metabolism, increase suboptimal thioguanine nucleotide (TGN) levels, normalize pathological liver function tests and improve clinical outcome. The magnitude of a skewed metabolism has not been assessed. Our aim was to evaluate the frequency of this phenomenon in a Swedish population of mainly IBD patients and its relationship to thiopurine methyltransferase (TPMT) function. Two typical clinical scenarios of a skewed metabolism in IBD, resistance to thiopurine therapy and hepatotoxicity, as well as the effect of a combination treatment with low-dose azathioprine and allopurinol are illustrated by two case reports.

2. Material, methods and results

2.1. Materials and methods

All thiopurine metabolite measurements in adult patients referred to the Division of Drug Research/Clinical Pharmacology in Linköping between January 2006 and April 2012 were assessed to evaluate the occurrence of a skewed thiopurine metabolism, which was defined as a ratio between methylated (methyl thioinosine monophosphate, meTIMP) and TGN metabolites above 20 in conjunction with a methylated metabolite level above 5000 pmol/8 × 10^8 red blood cells (RBC) and sub-therapeutic TGN levels (<250 pmol/8 × 10^8 RBC).

2.1.1. TPMT genotyping

DNA was isolated from whole blood using the QIAamp DNA mini kit (Qagen, Germany, Hilden). Three common variants in the TPMT gene (238G>C, 460G>A and 719A>G) were searched for by pyrosequencing as previously described.

2.1.2. TPMT enzyme activity assay in red blood cells

TPMT enzyme activity was measured as previously described in Pettersson et al. by determination of the formation of 6-methylmercaptopurine (6-meMP) from 6-mercaptopurine using radio-labeled S-adenosyl-l-methionine as the methyl donor. Product formation was measured using a scintillation counter. One unit of enzyme activity represents the formation of 1 nmol of 6-meMP per milliliter of packed red blood cells (pRBC) per hour of incubation. Cut-off points of 9.0 U/ml pRBC and 2.5 U/ml pRBC were used to distinguish high from intermediate enzyme activity and intermediate from low enzyme activity, respectively.

2.1.3. Determination of TGN and meTIMP

The concentrations of TGN and meTIMP were determined as described previously in washed red blood cells using HPLC. Results were expressed as pmol/8 × 10^8 RBC.

2.2. Results

A total of 4033 metabolite measurements, the vast majority (3686; 91%) referred from gastroenterologists, were performed in 2227 patients on at least 1 occasion per patient (range 1–23) and a skewed metabolism with high meTIMP metabolite levels (median 8700; range 5100–74,600 pmol/8 × 10^8 RBC), sub-therapeutic TGN levels (median 153; range 10–249 pmol/8 × 10^8 RBC) and a high meTIMP/TGN metabolite ratio (median 66.4; range 20.8–634.1) was observed in 319 (14.3%) patients on at least one of the measurements. A skewed metabolism was only observed in patients with a normal (wild-type) TPMT genotype. Although the TPMT activity was higher in patients with a skewed metabolism (13.9 vs. 13.0 U/ml RBC, P < 0.001) it was observed at all TPMT activity levels within the normal range (9.1–24.2 U/ml RBC).

2.3. Case 1 — The thiopurine-resistant patient

A 32-year old male was diagnosed with an ulcerative proctosigmoiditis in May 2007 and was started on a tapering course of prednisolon (30 mg daily) as well as topical steroids. He responded promptly but his disease flared after 6 months despite maintenance treatment with oral mesalamine. After two more courses with tapering steroids, azathioprine (AZA) was initiated in order to achieve steroid-free remission. The patient was found to have a normal TPMT enzyme activity (11.5 U/ml RBC) and the final AZA dose was estimated to 200 mg daily (2.0 mg/kg bodyweight (BW)/day). However, the dose was subsequently reduced to 150 mg due to lymphopenia. Measurement of thiopurine metabolites at this AZA dose revealed low TGN levels (118 pmol/8 × 10^8 RBC) and a meTIMP level of 2100 pmol/8 × 10^8 RBC. The disease remained active and the AZA dose was once again increased to 200 mg, but without any improvement in clinical symptoms. New metabolite measurements revealed a skewed metabolism with high meTIMP levels (9400 pmol/8 × 10^8 RBC) and low TGN levels (121 pmol/8 × 10^8 RBC) and a meTIMP/TGN ratio of 78 (Fig. 1).

In May 2009, the AZA dose was reduced to 50 mg and 100 mg of allopurinol was added two weeks later. After two weeks of combination therapy, the TGN level had increased to 269 pmol/8 × 10^8 RBC and the meTIMP levels had dropped to immeasurable levels. Within two months of combination treatment, this patient went into clinical remission. Repeated metabolite measurements have demonstrated stable thiopurine metabolite levels over time and this patient has continued to be in steroid-free remission for over 3 years.

2.4. Case 2 — The patient with hepatotoxicity

A 59-year old female was diagnosed with a distal colitis in 1989 which was successfully treated with oral sulfasalazine for many years. Due to recurrent steroid-requiring flares, up to two times per year, she was started on AZA in May 2010. The TPMT genotype and TPMT activity was normal (11.3 U/ml RBC) and...
the AZA dose was gradually raised to 200 mg daily (2.1 mg/kg BW/day). After two months of treatment, signs of mild hepatotoxicity with slightly elevated transaminases (ALT 1.9 ukat/L) were observed. The AZA dose was reduced to 150 mg and the liver tests improved marginally. Due to another flare in the disease, AZA was once again increased to 175 mg which resulted in a moderate rise in transaminases (ALT 3.3 ukat/L). The patient was considered intolerant to AZA and after a two week wash-out period with normalization of the liver tests she was switched to mercaptopurine (MP). When the MP dose was increased to 100 mg daily, hepatotoxicity with an ALT level of 3.4 ukat/L developed once again. An analysis of thiopurine metabolites was performed, which revealed a skewed metabolism with high methylated metabolites (meTIMP 11,400 pmol/8×10⁸ RBC), subtherapeutic TGN levels (185 pmol/8×10⁸ RBC) and a metabolite ratio of 62. Three months later, the patient was started on a low-dose AZA (50 mg daily) and 100 mg allopurinol was added two weeks later. When the metabolites were checked after two weeks, therapeutic TGN levels of 311 pmol/8×10⁸ RBC and undetected levels of meTIMP were observed. After two months of treatment, the patient complained about fatigue and metabolites were checked again. The TGN levels had increased to 476 pmol/8×10⁸ RBC and the meTIMP levels to 1000 pmol/8×10⁸ RBC. The AZA dose was subsequently reduced to 37.5 mg daily, which resulted in a drop of the TGN levels to 265 pmol/8×10⁸ RBC and only traces of meTIMP. The patient is still doing well without any signs of hepatotoxicity and she has had no flares since October 2010.

3. Discussion

A skewed thiopurine metabolism is a phenomenon characterized by excessive production of methylated metabolites in combination with sub-therapeutic TGN levels. Upon dose escalation the methylated metabolites will increase even further while the TGN levels remain on the same sub-therapeutic level or even decline. This is also a phenomenon of clinical importance since it has been associated with both toxicity and lack of efficacy.⁷

Our results indicate that a skewed metabolism is a common clinical phenomenon during thiopurine treatment, since every seventh patient in our database had a metabolite profile consistent with a skewed metabolism on at least one measurement. This finding is in accordance with other smaller studies.²,12 A limitation of the study is the lack of a widely accepted definition of a skewed metabolism as well as clinical evidence regarding therapeutic TGN levels.¹³⁻¹⁶ Furthermore, a skewed metabolism should ideally be assessed in a longitudinal rather than a cross-sectional study design.

Today, it is not possible to predict the occurrence of a skewed metabolism prior to initiating treatment with thiopurines. Our data strongly suggest that it only develops in patients with a normal TPMT genotype. The TPMT activity level, however, cannot predict a skewed metabolism. Instead, this phenomenon was observed at all TPMT activity levels within the normal range. This finding argues against the concept that very high TPMT activity levels generate hypermethylation and thus an increased risk of a skewed metabolism.¹⁷

As illustrated by the two cases a skewed metabolism can be successfully managed by a combination of a low-dose thiopurine in conjunction with allopurinol. The effects of this combination therapy have been known for several years and have been demonstrated by several small studies.⁴⁻⁸ In clinical practice, we have reduced the thiopurine dose to about 25 to 33% of the original dose and two weeks later added 100 mg of allopurinol. This treatment concept resulted in a very rapid metabolite shift which was followed.
by a resolution of pathological liver function tests and a prolonged clinical response. Alternative treatment options include 6-thioguanine, \(^1^9\) which produce similar metabolic profiles as a combination therapy with azathioprine and allopurinol, and the more unproven method of splitting the profiles as a combination therapy with azathioprine and (NRH) of the liver, \(^1^9\) but is considered safe and without risk of NRH if given in doses of 20 mg daily and if TGN levels remain \(< 600 \text{ pmol}/8 \times 10^8 \text{ RBC}\). \(^2^0^,^2^1\)

In conclusion, we have demonstrated that a skewed thiopurine metabolism may be a common clinical phenomenon that can develop at all TPMT activity levels within the normal range. We suggest that metabolite measurements should be considered in patients not responding to treatment and in those with hepatotoxicity or myelotoxicity in order to detect a skewed metabolism, since this phenomenon can be successfully managed by a combination of low-dose azathioprine and allopurinol. This may result in long-term disease remission and that other types of immunosuppression including treatment with anti-TNF antibodies can be avoided. Further studies, clarifying the impact of a skewed metabolism on both thiopurine efficacy and toxicity, are warranted as well as a consensus regarding the definition of a skewed metabolism.

**Funding**

None.

**Conflict of interest statement**

Neither of the authors have any conflict of interest with this manuscript.

**References**